Laverock Therapeutics raises £13.5m to accelerate gene silencing platform
Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to £13.5 million.
Stay updated with breaking news from Calculus Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to £13.5 million.
Laverock Therapeutics, established to commercialise the gene editing induced gene silencing platform for all human therapeutic applications has announced it has expanded its seed funding round to £13.5M.
Calculus has launched a £10m fundraise offer for its VCT, set to close on 30 August 2024.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
THIS DOCUMENT IS IMPORTANT AND REQUIRES IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take you are recommended to seek your own financial advice immediately...